blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2301967

EP2301967 - Single domain antibodies for nasal administration [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  08.06.2012
Database last updated on 02.09.2024
Most recent event   Tooltip08.06.2012Application deemed to be withdrawnpublished on 11.07.2012  [2012/28]
Applicant(s)For all designated states
Ablynx N.V.
Technologiepark 21
9052 Ghent-Zwijnaarde / BE
[2011/42]
Former [2011/13]For all designated states
Ablynx N.V.
Technologiepark 4
9052 Zwijnaarde / BE
Inventor(s)01 / Silence, Karen
Jean Tombeurstraat 21
B-3090, Overijse / BE
02 / Vaeck, Mark
Nieuwstraat 37
B-1981, Hofstade / BE
03 / Van Bergen en Henegouwen, Paul P.M.P.
Louis Bouwmeesterlaan 127
NL-3584, GE Utrecht / NL
 [2011/13]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[N/P]
Former [2011/13]HOFFMANN EITLE
Patent- und Rechtsanwälte Arabellastraße 4
81925 München / DE
Application number, filing date10178270.407.11.2003
[2011/13]
Priority number, dateUS20020425073P08.11.2002         Original published format: US 425073 P
US20020425063P08.11.2002         Original published format: US 425063 P
EP2003044700510.01.2003         Original published format: EP 03447005
WO2003EP0658123.06.2003         Original published format: PCT/EP0306/581
WO2003EP0731308.07.2003         Original published format: PCT/EP0307/313
[2011/13]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2301967
Date:30.03.2011
Language:EN
[2011/13]
Type: A3 Search report 
No.:EP2301967
Date:13.07.2011
[2011/28]
Search report(s)(Supplementary) European search report - dispatched on:EP16.06.2011
ClassificationIPC:C07K16/42, C07K16/24, C07K16/30, C07K16/12, C07K16/10, C07K16/40, C07K16/28, C12N15/13, A61K39/395, A61P11/06, A61P35/00, A61P31/06, A61P31/16
[2011/28]
CPC:
C07K16/2863 (EP,US); A61P1/00 (EP); A61P1/04 (EP);
A61P1/14 (EP); A61P1/16 (EP); A61P11/00 (EP);
A61P11/06 (EP); A61P13/00 (EP); A61P13/12 (EP);
A61P15/08 (EP); A61P17/02 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P21/04 (EP); A61P25/00 (EP);
A61P25/02 (EP); A61P27/02 (EP); A61P27/16 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P31/06 (EP);
A61P31/16 (EP); A61P35/00 (EP); A61P37/00 (EP);
A61P37/02 (EP); A61P37/06 (EP); A61P37/08 (EP);
A61P43/00 (EP); A61P5/00 (EP); A61P7/00 (EP);
A61P7/02 (EP); A61P7/06 (EP); A61P9/08 (EP);
A61P9/10 (EP); C07K16/18 (EP,US); C07K16/241 (EP,RU,US);
C07K16/249 (EP,US); C07K16/2875 (EP,US); C07K16/36 (EP,US);
C07K16/40 (EP,US); C07K16/4291 (EP,US); C07K16/468 (RU);
A61K2039/505 (EP,US); C07K2317/22 (EP,US); C07K2317/24 (EP,US);
C07K2317/31 (EP,US); C07K2317/565 (EP,US); C07K2317/569 (EP,US);
C07K2317/62 (EP,US); C07K2317/626 (EP,US); C07K2317/76 (EP,US);
C07K2317/77 (EP,US); C07K2319/00 (EP,US); C07K2319/31 (EP,US) (-)
Former IPC [2011/13]C07K16/18, A61K39/395, A61P29/00, A61P35/00, A61P37/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2011/13]
Extension statesAL22.09.2010
LT22.09.2010
LV22.09.2010
MK22.09.2010
TitleGerman:Einzeldomänenantikörper zur nasalen Verabreichung[2011/13]
English:Single domain antibodies for nasal administration[2011/13]
French:Anticorps à domaine unique pour administration nasale[2011/13]
Examination procedure22.09.2010Examination requested  [2011/13]
14.01.2012Application deemed to be withdrawn, date of legal effect  [2012/28]
21.02.2012Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2012/28]
Parent application(s)   TooltipEP03775004.9  / EP1558650
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20030775004) is  06.07.2006
Fees paidRenewal fee
22.09.2010Renewal fee patent year 03
22.09.2010Renewal fee patent year 04
22.09.2010Renewal fee patent year 05
22.09.2010Renewal fee patent year 06
22.09.2010Renewal fee patent year 07
22.09.2010Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
30.11.201109   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XYI]WO9710846  (INTRACEL CORP [US], et al) [X] 1-4,6 * page 14, line 11 - page 15, line 10 * [Y] 5,12,13 [I] 7-11,14,15;
 [Y]WO02080967  (NAT JEWISH MED & RES CENTER [US]) [Y] 5 * page 7, line 1; example 1; claim 25 *;
 [Y]WO9104054  (MILLAR ANN BRIGID [GB]) [Y] 8,9 * abstract * * claims 1,5 *;
 [Y]WO9102078  (PEPTIDE TECHNOLOGY LTD [AU]) [Y] 8,9 * page 4, lines 15-24 *;
 [A]WO02081649  (UNIV PENNSYLVANIA [US], et al) [A] 10,11 * claim 31 *;
 [AP]WO03002609  (MEDICAL RES COUNCIL [GB], et al) [AP] 1-15 * page 47, line 26 *
 [Y]  - "OMALIZUMAB - ANTI-IGE MONOCLONAL ANTIBODY E25, E25, HUMANISED ANTI-IGE MAB, IGE 025, MONOCLONAL ANTIBODY E25, OLIZUMAB, XOLAIR, RHUMAB-E25", BIODRUGS: CLINICAL IMMUNOTHERAPEUTICS, BIOPHARMACEUTICALS AND GENE THERAPY, ADIS INTERNATIONAL, FR, (20020101), vol. 16, no. 5, doi:10.2165/00063030-200216050-00009, ISSN 1173-8804, pages 380 - 386, XP009076298 [Y] 12,13 * abstract *

DOI:   http://dx.doi.org/10.2165/00063030-200216050-00009
 [A]  - MUYLDERMANS S, "SINGLE DOMAIN CAMEL ANTIBODIES: CURRENT STATUS", REVIEWS IN MOLECULAR BIOTECHNOLOGY, ELSEVIER, AMSTERDAM,, NL, (200106), vol. 74, no. 4, ISSN 1389-0352, pages 277 - 302, XP001057480 [A] 1-15 * table 1 *

DOI:   http://dx.doi.org/10.1016/S1389-0352(01)00021-6
by applicantUS4714759
 US4962035
 US4940782
 US4946788
 US5091313
 US5252467
 US5231026
 WO9304173
 US5428133
 US5422258
 EP0841946
 WO9404678
 WO9749805
 WO03035694
 EP0294703
 WO9634103
 EP0707473
 EP0684814
 US5629001
 US6514496
 US6267958
 US6190662
 WO0023471
 US6361938
 US5399346
 US4608392
 US4992478
 US4559157
 US4820508
 US4938949
 WO03054016
    - BANIYASH; ESHHAR, EUROPEAN JOURNAL OF IMMUNOLOGY, (1984), vol. 14, pages 799 - 807
    - RUP; KAHN, INTERNATIONAL ARCHIVES ALLERGY AND APPLIED IMMUNOLOGY, (1989), vol. 89, pages 387 - 393
    - BANIYASH ET AL., MOLECULAR IMMUNOLOGY, (1988), vol. 25, pages 705 - 711
    - HOOK ET AL., FEDERATION PROCEEDINGS, vol. 40, no. 3
    - PRESTA ET AL., J. IMMUNOL., (1993), vol. 151, pages 2623 - 2832
    - BLATTLER, BIOCHEMISTRY, vol. 24, pages 1517 - 1524
    - SAMBROOK ET AL., Molecular Cloning, Laboratory Manuel, COLD SPRING, HARBOR LABORATORY PRESS
    - MUYLDERMANS, S., REVIEWS IN MOLECULAR BIOTECHNOLOGY, (2001), vol. 74, pages 277 - 303
    - PARTRIDGE, ADV. DRUG DELIVERY REVIEWS, (1995), vol. 15, pages 5 - 36
    - POUL MA ET AL., J MOL BIOL, (2000), vol. 301, pages 1149 - 1161
    - CARMAN, C.V.; BENOVIC, J.L., CURRENT OPINION IN NEUROBIOLOGY, (1998), vol. 8, pages 335 - 344
    - KASSNER, BIOCHEM BIOPHYS RES COMMUN, (1999), vol. 264, pages 921 - 928
    - LAROCCA D ET AL., CURR. PHARM. BIOTECHNOL, (2002), vol. 3, pages 45 - 57
    - MUYIDERMANS, S., REVIEWS IN MOLECULAR BIOTECHNOLOGY, (2001), vol. 74, pages 277 - 303
    - MARTIN, E.W., Remington's Pharmaceutical Sciences, ed. 4, MACK PUBLISHING CO.
    - MAGNI ET AL., ANAL BIOCHEM, (2001), vol. 298, pages 181 - 188
    - J. BIOI. CHEM., (1921), vol. 49, page 183
    - OKAYASU ET AL., GASTROENTEROLOGY, (1990), vol. 98, pages 694 - 702
    - G. KOJOUHAROFF, CLIN. EXP. IMMUNOL., (1997), vol. 107, pages 353 - 8
    - G. KOJOUHAROFF ET AL., CIIN. EXP. IMMUNOL., (1997), vol. 107, pages 353 - 8
    - COHEN S; USHIRO H; STOSCHECK C; CHINKERS M, "A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles", J. BIOL. CHEM., (1982), vol. 257, pages 1523 - 31
    - CHOMCZYNSKI P; SACCHí N, "Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction", ANAL BIOCHEM, (1987), vol. 162, pages 156 - 159
    - DE HAARD HJ; VAN NEER N; REURS A; HUFTON SE; ROOVERS RC; HENDERIKX P; DE BRUINE AP; ARENDS JW; HOOGENBOOM HR, "A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies", J. BIOI. CHEM., (1999), vol. 274, pages 18218 - 30
    - DEFIZE LH; MOOLENAAR WH; VAN DER SAAG PT; DE LAAT SW, "Dissociation of cellular responses to epidermal growth factor using anti-receptor monoclonal antibodies", EMBO J., (1986), vol. 5, pages 1187 - 92
    - SATO JD; KAWAMOTO T; LE AD; MENDELSOHN J; POLIKOFF J; SATO GH, "Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors", MOL. BIO!. MED., (1983), vol. 1, pages 511 - 529
    - POUL MA; BECERRIL B; NIELSEN UB; MORISSON P; MARKS JD, "Selection of tumor-specific internalizing human antibodies from phage libraries", J. MOL, BIOL., (2000), vol. 301, pages 1149 - 61
    - POUL MA, J MOL BIOL, (1999), vol. 288, pages 203 - 211
    - LAROCCO, MOLECULAR THERAPY, (2001), vol. 3, pages 476 - 484
    - POUL MA ET AL., J MOL BIOL, (1999), vol. 288, pages 203 - 211
    - CONRATH ET AL., J BIOI CHEM, (2001), vol. 276, pages 7346 - 7350
    - OKAYASU 1; HATAKEYAMA S; YAMADA M; OHKUSA T; INAGAKI Y; NAKAYA R, "A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice", GASTROENTEROLOGY, (1990), vol. 98, pages 694 - 702
    - KOJOUHAROFF G; HANS W; OBERMEIER F; MANNEL DN; ANDUS T; SCHOLMERICH J; GROSS V; FALK W, "Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice", CLIN EXP IMMUNOL, (1997), vol. 107, pages 353 - 8
    - SALMELA MT; PENDER SL; REUNALA T; MACDONALD T; SAARIALHO-KERE U., GUT, (2001), vol. 48, no. 4, pages 496 - 502
    - CHAVEY C; MARI B; MONTHOUEL MN; BONNAFOUS S; ANGLARD P; VAN OBBERGHEN E; TARTARE-DECKERT S., J. BIOL. CHEM., (2003), vol. 278, pages 11888 - 11896
    - CHURG A; WANG RD; TAI H; WANG X; XIE C; DAI J; SHAPIRO SD; WRIGHT JL, AM. J. RESPIR. CRIT. CARE MED., (2003), vol. 167, pages 1083 - 1089
    - R LANG; A KOCOUREK; M BRAUN; H TSCHESCHE; R HUBER; W BODE; K MASKOS, J MOL BIOL, (200109), vol. 312, no. 4, pages 731 - 42
    - YOSHIKATSU KANEKO; MINORU SAKATSUME; YUANSHENG XIE; TAKESHI KURODA; MICHIKO LGASHIMA; ICHIEI NARITA; FUMITAKE GEJYO, THE JOURNAL OF IMMUNOLOGY, (2003), vol. 170, pages 3377 - 3385
    - DING Y; SHIMADA Y; GORRIN-RIVAS MJ; ITAMI A; LI Z; HONG T; MAEDA M; KOMOTO I; KAWABE A; KAGANOI J, ONCOLOGY, (2002), vol. 63, no. 4, pages 378 - 84
    - KERKELA E; ALA-AHO R; JESKANEN L; RECHARDT 0; GRENMAN R; SHAPIRO SD; KAHARI VM; SAARIALHO-KERE U, J INVEST DERMATOL, (200006), vol. 114, no. 6, pages 1113 - 9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.